Testing a dye that may show the edges of a brain tumor during surgery
Original title: Fluorescence-Guided Imaging of Brain Tumors: A Safety Study Using SBK2-ICG
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early safety test in people.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
Doctors are testing a dye that may help them see where a brain tumor ends.
Who this trial is for. This study is for people who have, or may have, a brain tumor that is usually treated with surgery. They get a drug called SBK2-ICG about an hour before surgery, and the surgery itself is not changed.
Where it stands. This trial has not reported results. Researchers want to learn the best dose of SBK2-ICG for showing the border between tumor and normal brain. That answer is not in yet.
What this means, and what it doesn't
What it could mean: If the dye works, surgeons may be able to see tumor edges more clearly and leave more healthy brain alone. Someone who fits this study could ask their care team about it.
What it doesn't mean: This does not mean SBK2-ICG is a proven treatment. A trial is a test, not care you can count on. Being in a trial is not a promise that it will help you. It is not a cure. The FDA has not approved this drug to locate brain tumors.
Source: ClinicalTrials.gov, October 6, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.